Amphista Therapeutics Receives FDA Clearance for AMX-883 AML Trial
CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Blood Cancer
Advertisement
Stelexis BioSciences Reports Breakthrough Phase 1 Eganelisib Results in AML and MDS
WALTHAM, Massachusetts, USA, June 2, 202 Stelexis BioSciences has announced encouraging Phase 1 clinical trial results for eganelisib, its...
AvenCell Therapeutics to Present First Phase 1 Results for Switchable Allogeneic CAR-T Therapy in AML
WATERTOWN, Massachusetts, USA & DRESDEN, Germany, June 2, 2026 AvenCell Therapeutics has announced that it will present results from...
Karyopharm Highlights Phase 3 SENTRY Trial Progress in Myelofibrosis
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
Solu Therapeutics Wins FDA Fast Track for STX-0712
BOSTON, Mass., May 27, 2026 Solu Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Advertisements
AbbVie Wins FDA Approval for DECNUPAZ in Rare Blood Cancer
NORTH CHICAGO, Ill., May 27, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ™...
Moleculin Nears Key MIRACLE AML Trial Data Milestone
HOUSTON, May 15, 2026 Moleculin Biotech reported first quarter 2026 financial results while advancing its pivotal MIRACLE Phase 2B/3...
BeOne Medicines Wins FDA Approval for BEQALZI in Mantle Cell Lymphoma
SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...
Ascentage Pharma Highlights Hematology Pipeline at EHA
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 Ascentage Pharma announced that 17 major clinical advances across its hematology...
Advertisement
